Summarized by Masters of Longevity from LinkedIn.
February corporate recap: $772M+ in venture funding, $22.2B+ in acquisitions, and $198M+ in IPO value. Highlights include Talkiatry's $210M Series D, Lotus Health AI's $41M raise, Big Health's $23.7M, Temple's $54M valuation, AstraZeneca's $18.5B deal with CSPC Pharmaceutical Group, and Eli Lilly's up-to-$2.4B acquisition of Orna Therapeutics. Deals span AI primary care, digital therapeutics, women's precision health, PFAS-focused probiotics, athlete wearables, and consumer 'better-for-you' brands.
